Fig. 1From: Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trialPatient screening and inclusion. Screening and inclusion flowchart. Of the 67 randomized patients, 66 patients were included in the final analysis and 64 patients received at least one dose of the study medicationBack to article page